具有中间雌激素受体表达的乳腺癌:特征,预后和治疗
1Algoma District Cancer Program, Sault Area Hospital, Sault Ste Marie, Ontario, Canada; Division of Clinical Sciences, Section of Internal Medicine, Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
Clinical breast cancer
|December 22, 2024
概括
雌激素受体 (ER) 阳性乳腺癌的中间表达 (10-90%) 是鲜为人知的. 本综述探讨了它们的基因组概况和治疗影响,突出了ER阳性乳腺癌中一个独特的子组.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 雌激素受体 (ER) 是乳腺癌的关键生物标志物,指导ER阳性瘤的激素治疗.
- 目前的ER状态 (≥1%的瘤细胞) 定义了治疗,但反应与表达水平有很大差异.
- 低ER表达 (1-10%) 与荷尔蒙治疗反应不佳相关,类似于ER阴性癌症.
研究的目的:
- 调查ER阳性乳腺癌的基因组景观,其中中间的ER表达 (10-90%).
- 检查这种异质子组的治疗影响和临床行为.
- 为了澄清ER表达级别在当前二进制分类之外的作用.
主要方法:
- 对乳腺癌基因组学和生物标志物表达的现有文献的综述.
- 对专注于ER阳性乳腺癌,具有不同程度的ER表达的研究的分析.
- 检查了将ER表达与对荷尔蒙疗法的反应相关联的数据.
主要成果:
- 具有中间ER表达 (10-90%) 的乳腺癌代表了一个异质的群体.
- 基因组分析揭示了这个子组内的独特分子特征.
- 在中等ER表达瘤中,对激素治疗的反应比在高ER表达瘤中更难预测.
结论:
- 目前的ER分类可能过于简化了乳腺癌生物学和治疗反应.
- 中间ER表达值得进一步研究以优化个性化治疗策略.
- 了解这一亚组的基因组异质性对于改善瘤学患者的治疗结果至关重要.
相关概念视频
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


